Jump to: Authorized Access | Attribution | Authorized Requests

Study Description

In this study, we tested whether type I interferons (IFN-I), namely IFN-alpha and IFN-beta, may promote Mycobacterium tuberculosis (Mtb) pathogenesis by exacerbating cell death of human monocyte-derived macrophages (MDM) infected with Mtb. We differentiated the MDM under two different published methods (see Document Method.pdf for Table 1 of Methods). To determine if MDM infected with Mtb upregulates IFN-I transcripts, signaling factors, or IFN-I stimulated genes (ISGs), the MDM were infected with Mtb or treated with an activator of stimulator of IFN genes (STING), diamidobenzimidazole (di-ABZI). STING activation acted as a positive control for IFN-I induction and ISG upregulation. Indeed, di-ABZI treated MDM differentiated under both methods upregulated ISGs 24 hpi. At 24 hour post treatment, MDM differentiated under one method, but not under another method, upregulated ISGs, such as ISG15, IFITM3, and CXCL10, upon Mtb infection. MDM differentiated under both methods upregulated ISGs upon di-ABZI treatment.

Authorized Access
Publicly Available Data
  Link to other NCBI resources related to this study
Study Inclusion/Exclusion Criteria

Inclusion Criteria:

  • healthy adult donors only
Selected Publications
Diseases/Traits Related to Study (MeSH terms)
Links to Related Genes
Authorized Data Access Requests
Study Attribution
  • Principal Investigator
    • Carl Nathan. Weill Cornell Medicine, New York, NY, USA.
  • Co-Investigators
    • Angela Lee. Weill Cornell Medicine, New York, NY, USA.
    • Kohta Saito. Weill Cornell Medicine, New York, NY, USA.
    • Christopher Brown. Weill Cornell Medicine, New York, NY, USA.
    • Kathryn Dupnik. Weill Cornell Medicine, New York, NY, USA.
  • Sequencing Center
    • Weill Cornell Medicine Genetics Core. Weill Cornell Medicine, New York, NY, USA.
  • Bioinformatician at Sequencing Center
    • Adrian Tan. Weill Cornell Medicine, New York, NY, USA.
  • Funding Sources
    • RO1 AI138940. National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
    • Abby and Howard P. Milstein Program in Chemical Biology and Translational Medicine. Weill Cornell Medicine, New York, NY, USA.